Roche Receives FDA Approval for Tecentriq Plus Avastin in Frontline Hepatocellular Carcinoma

Roche today announced that the FDA has approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC). In the Phase 3 IMbrave150 trial, Tecentriq plus Avastin demonstrated a statistically significant improvement in overall survival and progression-free survival compared to sorafenib. The median OS was 19.2 months for Tecentriq plus Avastin versus 13.4 months for sorafenib. This approval establishes Tecentriq plus Avastin as a new standard of care in the first-line treatment of unresectable HCC.